Cargando…

Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review

Compounds known to be successful in the treatment of alcohol use disorder include the aversive agent, Disulfiram, the glutamatergic NMDA receptor antagonist, Acamprosate, and the opioid receptor antagonists, Naltrexone and Nalmefene. Although all four are effective in maintaining abstinence or reduc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fischler, Pascal Valentin, Soyka, Michael, Seifritz, Erich, Mutschler, Jochen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574013/ https://www.ncbi.nlm.nih.gov/pubmed/36263121 http://dx.doi.org/10.3389/fphar.2022.927703

Ejemplares similares

Recommendations on Off-Label Drug Use in Pediatric Guidelines
por: Meng, Min, et al.
Publicado: (2022)

Utilisation of drugs for the treatment of psychiatric diseases in the pediatric population: focus on off-label use
por: Pesiou, Stella, et al.
Publicado: (2023)

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review
por: Soyka, Michael
Publicado: (2021)

Recommendations for Off-Label Drug Use in Ophthalmology in China: A Clinical Practice Guideline
por: Li, Guangyao, et al.
Publicado: (2022)

Case Report: Off-label treatment of idiopathic hypereosinophilic syndrome with Omalizumab
por: Zhang, Zhiyu, et al.
Publicado: (2023)

On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients
por: Verbaanderd, Ciska, et al.
Publicado: (2020)

Safety of Off-Label Pharmacological Treatment in Pediatric Neuropsychiatric Disorders: A Global Perspective From an Observational Study at an Italian Third Level Children’s Hospital
por: Giurin, Maria Sole, et al.
Publicado: (2022)

Off-label drug prescriptions in French general practice: a cross-sectional study
por: Drogou, François, et al.
Publicado: (2019)

Off-Label Use of Antineoplastic Drugs to Treat Malignancies: Evidence From China Based on a Nationwide Medical Insurance Data Analysis
por: Wei, Guoxu, et al.
Publicado: (2021)

Prescription Pattern and Off-Label Use of Antipsychotics in a Middle Eastern Population
por: Bastaki, Kholoud, et al.
Publicado: (2021)

Treatment of opioid dependence with buprenorphine: current update
por: Soyka, Michael
Publicado: (2017)

Probiotics-Based Treatment as an Integral Approach for Alcohol Use Disorder in Alcoholic Liver Disease
por: Fuenzalida, Catalina, et al.
Publicado: (2021)

Harnessing the potential of probiotics in the treatment of alcoholic liver disorders
por: Mishra, Garima, et al.
Publicado: (2023)

Label-free drug discovery
por: Fang, Ye
Publicado: (2014)

Editorial: Investigating drugs used off-label in various cancers
por: Liu, Wang, et al.
Publicado: (2023)

Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System
por: Gordon, Noa, et al.
Publicado: (2021)

The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting
por: Herrero Fernandez, Marta, et al.
Publicado: (2019)

Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis
por: Shen, Nan-Nan, et al.
Publicado: (2021)

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study
por: Vitale, Antonio, et al.
Publicado: (2016)

Evaluation of Kratom Opioid Derivatives as Potential Treatment Option for Alcohol Use Disorder
por: Gutridge, Anna M., et al.
Publicado: (2021)

Development of the First Value Assessment Index System for Off-Label Use of Antineoplastic Agents in China: A Delphi Study
por: Jiang, Qian, et al.
Publicado: (2020)

Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database
por: Gozzo, Lucia, et al.
Publicado: (2021)

Off-label drugs for obesity
por: Morgan, Andy, et al.
Publicado: (2022)

GABA(B) receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence
por: Agabio, Roberta, et al.
Publicado: (2014)

A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology (A Case Study in Glioblastoma)
por: Agrawal, Samir, et al.
Publicado: (2019)

Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System
por: Mascolo, Annamaria, et al.
Publicado: (2020)

The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use
por: Yunusa, Ismaeel, et al.
Publicado: (2020)

Structural basis of empathy and the domain general region in the anterior insular cortex
por: Mutschler, Isabella, et al.
Publicado: (2013)

Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain
por: De Ternay, Julia, et al.
Publicado: (2019)

Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder
por: Ho, Ming-Fen, et al.
Publicado: (2022)

Impact of Three Safety Interventions Targeting Off-Label Use of Immediate-Release Fentanyl on Prescription Trends: Interrupted Time Series Analysis
por: García-Sempere, Aníbal, et al.
Publicado: (2022)

Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update
por: Bustillo, Juan R.
Publicado: (2013)

Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review
por: Wadaa-Allah, Ahmed, et al.
Publicado: (2021)

LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation
por: Kraehenmann, Rainer, et al.
Publicado: (2017)

Expression of Concern: A new method for ethical and efficient evidence generation for off-label medication use in oncology (a case study in glioblastoma)
Publicado: (2023)

Targeting glutamate uptake to treat alcohol use disorders
por: Rao, P.S.S., et al.
Publicado: (2015)

Zebrafish as a Model for Fetal Alcohol Spectrum Disorders
por: Alsakran, Amena, et al.
Publicado: (2021)

Nicotinic receptor modulation to treat alcohol and drug dependence
por: Rahman, Shafiqur, et al.
Publicado: (2015)

Multiple drugs: Critical illness myopathy following off-label use: case report
Publicado: (2021)

Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use
por: Bouhuys, Marleen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pdnkifpi5hja5qc1heo06q99jp